• Cardiovascular Drugs, Perindopril + Amlodipine
    Dosage form: Tablet
    Strength: 3.5+2.5mg; 5+5mg; 7+5mg; 10+10mg; 14+10mg
    Indications/Special comments: Treatment of hypertension in patients not adequately controlled with monotherapy or as initial therapy in patients that require multiple antihypertensive for adequate control.
    Dosage Administration: Hypertension: Adults: Oral: Initial: Perindopril 3.5mg/amlodipine 2.5 mg once daily; adjust dose to response in 7 to 14 day intervals; maximum dose: perindopril 14mg/amlodipine 10mg once daily. Note: Not recommended in patients >65 years of age.
    View full drug info
  • Blood products and drugs affecting blood, Phytomenadione (Vitamin K1)
    Dosage form: Tablet
    Strength: 10mg
    Indications/Special comments: For the treatment of haemorrhage due to Vitamin k deficiency. Prothrombogenic nutritional supplement, it is also used for treatment and prevention of various coagulation disorders including hypoprothrombinemia, or as an antidote to drug induced hypoprothrombinemia
    Dosage Administration: Adult: Nutritional supplement (Vitamins), prothrombogenic or Antidote (to drug-induced hypoprothrombinemia): 2.5 to 10mg (up to 25mg), may be repeated after 6 - 8 hours if necessary
    View full drug info
  • Blood products and drugs affecting blood, Phytomenadione (Vitamin K1)
    Dosage form: Injection
    Strength: 1mg/ml, 10mg/ml in 1ml ampoule.
    Indications/Special comments: For the treatment of haemorrhage due to Vitamin k deficiency.
    Dosage Administration: Subcutaneously or intramuscularly. It should not be given repeatedly to patient with severe liver diseases, once the response to the initial dose is unsatisfactory. Adult: I.M. or S.C., 2.5 – 10mg (up to 25mg), may be repeated after 6 - 8 hours if necessary. Child: Infants - IM or SC, 1 - 2mg; Child - IM or SC, 5 - 10mg.
    View full drug info
  • Anxiolytics, Sedatives, Hypnotics and Antipsychotics, Promethazine
    Dosage form: Injection
    Strength: 25mg/ml, 50mg/2ml
    Indications/Special comments: Night sedation and insomnia or it is indicated as sedative hypnotic.
    Dosage Administration: Adult: Oral: 25mg at bed time, increased to 50mg if necessary. Child (2 - 5 years): 15 to 20mg; 5 - 10 years: 20 to 25mg at bed time.
    View full drug info
  • Anxiolytics, Sedatives, Hypnotics and Antipsychotics, Phenobarbitone (Phenobarbital)
    Dosage form: Tablet
    Strength: 10mg, 15mg, 30mg, 60mg, and 100mg
    Indications/Special comments: Sedative-hypnotic
    Dosage Administration: Sedative: Oral: Adult: daytime- 30 - 120mg (base) in two or three divided doses a day; Child: daytime, 2mg (base)/kg of body weight three times a day; Preoperative, 1 to 3mg (base) per kg of body weight. Hypnotic: Adult: Oral: 100 to 320mg (base) at bedtime
    View full drug info
  • Anxiolytics, Sedatives, Hypnotics and Antipsychotics, Phenobarbitone (Phenobarbital)
    Dosage form: Elixir
    Strength: 20mg/5ml
    Indications/Special comments: Sedative-hypnotic
    Dosage Administration: Hypnotic: Adult: Oral: 100 to 320mg (base) at bedtime; IM or IV: 100 to 325mg. Child: dosage must be individualized by physician. Sedative: Oral: Adult: daytime- 30 - 120mg (base) in two or three divided doses a day; Child: daytime, 2mg (base)/kg of body weight three times a day; Preoperative, 1 to 3mg (base) per kg of body weight. IM or IV: Adult: daytime, 30 to 120mg a day in two or three divided doses, preoperative (IM), 130 - 200mg
    View full drug info
  • Anxiolytics, Sedatives, Hypnotics and Antipsychotics, Phenobarbitone (Phenobarbital
    Dosage form: Injection
    Strength: 30mg/ml, 100mg/ml
    Indications/Special comments: Sedative-hypnotic
    Dosage Administration: Hypnotic: Adult: IM or IV: 100 to 325mg. Child: dosage must be individualized by physician. Sedative: IM or IV: Adult: daytime, 30 to 120mg a day in two or three divided doses, preoperative (IM), 130 - 200mg.
    View full drug info
  • Antineoplastics and Related Agents, Pertuzumab
    Dosage form: Injection
    Strength: 420mg
    Indications/Special comments: Treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel, in patients who have not received previous anti-HER2 therapy or chemotherapy (initiated by a specialist.
    Dosage Administration: Adults: Breast Cancer: Pertuzumab, trastuzumab, and docetaxel for HER2-overexpressing Metastatic Breast Cancer: IV. Initially, pertuzumab 840mg in combination with trastuzumab 8mg/kg (administered by IV infusion over 90 minutes) and docetaxel 75mg/m2 (administered by IV infusion), followed every 3 weeks thereafter by pertuzumab 420mg in combination with trastuzumab 6mg/kg (administered by IV infusion over 30 – 90 minutes) and docetaxel 75 or 100mg/m2. If a dose is missed or delayed, and the time between 2 sequential infusions is <6 weeks, administer pertuzumab 420 mg; do not wait until the next scheduled dose. If the time between 2 sequential infusions is =6 weeks, administer pertuzumab dose of 840mg (i.e., same dose as initially used), followed by pertuzumab 420mg every 3 weeks thereafter.
    View full drug info
  • Antineoplastics and Related Agents, Pemetrexed
    Dosage form: Injection
    Strength: 100mg, 500mg
    Indications/Special comments: Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin). First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin). Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy). Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy).
    Dosage Administration: Usual Adult Dose for Malignant Pleural Mesothelioma:Initial Dose: 500mg/m2 of pemetrexed administered as an intravenous infusion over 10 minutes on day 1 of each 21 day cycle along with cisplatin. Cisplatin 75mg/m² infused over 2 hours beginning approximately 30 minutes after the end of the pemetrexed administration. Patients should receive hydration consistent with local practice prior to and/or after receiving cisplatin. Pretreatment with dexamethasone (or equivalent) reduces the incidence and severity of cutaneous reactions. Administer dexamethasone 4mg orally twice a day, on the day before, the day of, and the day after pemetrexed administration. Usual Adult Dose for Non-Small Cell Lung Cancer: Initial Dose: 500mg/m² of pemetrexed administered as an intravenous infusion over 10 minutes on day 1 of each 21 day cycle. Pretreatment with dexamethasone (or equivalent) reduces the incidence and severity of cutaneous reactions. Administer dexamethasone 4mg orally twice a day, on the day before, the day of, and the day after pemetrexed administration.
    View full drug info
  • Antineoplastics and Related Agents, Paclitaxel
    Dosage form: Injection
    Strength: 300mg
    Indications/Special comments: Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only), Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only). Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only). Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only). Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only). Treatment of advanced AIDS-related Kaposi's sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only). First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only). Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only). In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only).
    Dosage Administration: See product insert
    View full drug info